ABSTRACT
Background Widespread reports suggest the characteristics and disease course of coronavirus disease 2019 (COVID-19) and influenza differ, yet detailed comparisons of their clinical manifestations are lacking.
Objective Comparison of the epidemiology and clinical characteristics of COVID-19 patients with those of influenza patients in previous seasons at the same hospital
Design Admission rates, clinical measurements, and clinical outcomes from confirmed COVID-19 cases between March 1 and April 30, 2020 were compared with those from confirmed influenza cases in the previous five influenza seasons (8 months each) beginning September 1, 2014.
Setting Large tertiary care teaching hospital in Boston, Massachusetts
Participants Laboratory-confirmed COVID-19 and influenza inpatients
Measurements Patient demographics and medical history, mortality, incidence and duration of mechanical ventilation, incidences of vasopressor support and renal replacement therapy, hospital and intensive care admissions.
Results Data was abstracted from medical records of 1052 influenza patients and 583 COVID-19 patients. An average of 210 hospital admissions for influenza occurred per 8-month season compared to 583 COVID-19 admissions over two months. The median weekly number of COVID-19 patients requiring mechanical ventilation was 17 (IQR: 4, 34) compared to a weekly median of 1 (IQR: 0, 2) influenza patient (p=0.001). COVID-19 patients were significantly more likely to require mechanical ventilation (31% vs 8%), and had significantly higher mortality (20% vs. 3%; p<0.001 for all). Relatively more COVID-19 patients on mechanical ventilation lacked pre-existing conditions compared with mechanically ventilated influenza patients (25% vs 4%, p<0.001).
Limitation This is a single-center study which could limit generalization.
Conclusion COVID-19 resulted in more hospitalizations, higher morbidity, and higher mortality than influenza at the same hospital.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported with internal funds.
Dr. Donnino is supported, in part, by grants from the National Institutes of Health K24HL127101 R01HL136705 and 1R01DK112886.
Dr. Moskowitz is supported, in part, by a grant from the National Institutes of Health K23GM128005.
Dr. Berg is supported, in part, by a grant from the National Institutes of Health 5K23HL12881404.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Determination of Exemption IRB Protocol #: 2020P000428 Principal Investigator: Michael Donnino Protocol Title: Clinical Characteristics of Influenza and COVID19 Patients Funding: None Review Type: Exempt - Categories: 4 IRB Determination Date: 04/21/2020 Notification Date: 04/27/2020 The Beth Israel Deaconess Medical Center Committee on Clinical Investigations has determined that the referenced application meets the criteria for exempt status under exempt category/categories: 4. HIPAA Waiver of Authorization is approved. When the CCI determines that a study is exempt continuing review and approval is not required. In some circumstances, modifications to exempt research disqualify the research from the exempt status. Modifications that could increase the risk level, alter the study design or population, or involve a change in PI must be submitted to the CCI for review and approval prior to implementation. PLEASE NOTE: You are reminded that you are required to follow the requirements described in the CCI Policy and Procedure Manual. If there are any questions you may contact the Committee on Clinical Investigations (CCI) at 617-975-8511. cc: Amanda Frias-Howard
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
THe data is maintained by the authors who can be contacted for further queries.